Skip to main content
. 2024 Aug 19;15:1446748. doi: 10.3389/fimmu.2024.1446748

Figure 1.

Figure 1

A clinical decision support tool should be capable of visualizing the very heterogenous MS patient data, the AI-supported analysis of this data and the outcome of prognostic models using this data, enabling a data-driven discussion between the neurologist and patient to identify the best DMT for the patient.